肌层浸润性膀胱癌的放化疗:3期随机对照BC2001试验10年随访
BC2001试验纳入458例T2-T4a N0M0肌层浸润性膀胱癌患者,随机接受放疗或放化疗。中位随访9.9年显示,放化疗改善局部区域控制(HR 0.61,95%CI 0.43-0.86,p=0.004)和无浸润性局部区域控制(HR 0.55,95%CI 0.36-0.84,p=0.006),5年膀胱切除率放化疗组14% vs 单纯放疗组22%(HR 0.54,95%CI 0.31-0.95,p=0.034)。
要点
- 放化疗较单纯放疗改善局部区域控制,HR 0.61(95%CI 0.43-0.86,p=0.004)。
- 放化疗较单纯放疗改善无浸润性局部区域控制,HR 0.55(95%CI 0.36-0.84,p=0.006)。
- 5年膀胱切除率放化疗组14% vs 单纯放疗组22%,HR 0.54(95%CI 0.31-0.95,p=0.034)。
核心结论
- 长期随访结果证实,在放疗基础上联合同步5-氟尿嘧啶和丝裂霉素C对肌层浸润性膀胱癌的获益得以维持。
研究设计与样本
- 3期随机对照2×2析因试验,2001年至2008年纳入458例T2-T4a N0M0肌层浸润性膀胱癌患者。
- 360例随机分配至放疗组(178例)或放化疗组(182例);218例随机分配至标准全膀胱放疗组(108例)或减少高剂量体积放疗组(111例)。
- 中位随访时间9.9年,试验注册号ISRCTN68324339。
- 放疗方案:55 Gy分20次4周内完成,或64 Gy分32次6.5周内完成;同步化疗:5-氟尿嘧啶和丝裂霉素C。
- 疗效分析采用意向性治疗原则,使用Cox回归。
主要发现
- 放化疗较单纯放疗改善局部区域控制,HR 0.61(95%CI 0.43-0.86,p=0.004)。
- 放化疗较单纯放疗改善无浸润性局部区域控制,HR 0.55(95%CI 0.36-0.84,p=0.006)。
- 疾病相关结局的获益未达统计学显著:无病生存HR 0.78(95%CI 0.60-1.02,p=0.069),无转移生存HR 0.78(95%CI 0.58-1.05,p=0.089),总生存HR 0.88(95%CI 0.69-1.13,p=0.3),膀胱癌特异性生存HR 0.79(95%CI 0.59-1.06,p=0.11)。
- 5年膀胱切除率放化疗组14%(95%CI 9-21%)vs 单纯放疗组22%(95%CI 16-31%),HR 0.54(95%CI 0.31-0.95,p=0.034)。
- 标准全膀胱放疗与减少高剂量体积放疗之间未见差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer (MIBC), demonstrated improvement in locoregional control by adding fluorouracil and mitomycin C to radiotherapy (James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477-88). There are limited data on long-term recurrence risk. OBJECTIVE: To determine whether benefit of adding chemotherapy to radiotherapy for MIBC is maintained in the long term. DESIGN, SETTING, AND PARTICIPANTS: A phase 3 randomised controlled 2 × 2 factorial trial was conducted. Between 2001 and 2008, 458 patients with T2-T4a N0M0 MIBC were enrolled; 360 were randomised to radiotherapy (178) or chemoradiotherapy (182), and 218 were randomised to standard whole-bladder radiotherapy (108) or reduced high-dose-volume radiotherapy (111). The median follow-up time was 9.9 yr. The trial is registered (ISRCTN68324339). INTERVENTION: Radiotherapy: 55 Gy in 20 fractions over 4 wk or 64 Gy in 32 fractions over 6.5 wk; concurrent chemotherapy: 5-fluorouracil and mitomycin C. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Locoregional control (primary endpoint), invasive locoregional control, toxicity, rate of salvage cystectomy, disease-free survival (DFS), metastasis-free survival (MFS), bladder cancer-specific survival (BCSS), and overall survival. Cox regression was used. The analysis of efficacy outcomes was by intention to treat. RESULTS AND LIMITATIONS: Chemoradiotherapy improved locoregional control (hazard ratio [HR] 0.61 [95% confidence interval {CI} 0.43-0.86], p = 0.004) and invasive locoregional control (HR 0.55 [95% CI 0.36-0.84], p = 0.006). This benefit translated, albeit nonsignificantly, for disease-related outcomes: DFS (HR 0.78 [95% CI 0.60-1.02], p = 0.069), MFS (HR 0.78, [95% CI 0.58-1.05], p = 0.089), overall survival (HR = 0.88 [95% CI 0.69-1.13], p = 0.3), and BCSS (HR 0.79 [95% CI 0.59-1.06], p = 0.11). The 5-yr cystectomy rate was 14% (95% CI 9-21%) with chemoradiotherapy versus 22% (95% CI 16-31%) with radiotherapy alone (HR 0.54, [95% CI 0.31-0.95], p = 0.034). No differences were seen between standard and reduced high-dose-volume radiotherapy. CONCLUSIONS: Long-term findings confirm the benefit of adding concomitant 5-fluorouracil and mitomycin C to radiotherapy for MIBC. PATIENT SUMMARY: We looked at long-term outcomes of a phase 3 clinical trial testing radiotherapy with or without chemotherapy for patients with invasive bladder cancer. We concluded that the benefit of adding chemotherapy to radiotherapy was maintained over 10 yr.
引用
- Hall E, Hussain SA, Porta N, et al. Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. Eur Urol. 2022. PMID: 35577644. doi:10.1016/j.eururo.2022.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。